- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04223479
Effect of Probiotic Supplementation on the Immune System in Patients With Ulcerative Colitis in Amman, Jordan
Ulcerative colitis (UC) is a chronic Inflammatory bowel disease (IBD) that most likely results from the interaction between various environmental and genetic factors. Using probiotics as an adjunct to medical therapy might be useful in the treatment of UC and improving the symptoms of the disease. The result of studies that investigate the role of Probiotics supplementation in improving the inflammatory response, immune response and life quality of patients with the UC is not conclusive. So, this study aimed to study the effect of probiotics on the response of inflammatory markers, immune response, and quality of life in patients with UC.
An interventional double-blind randomized clinical trial (RCT) design will be used in this study. Forty patients will be recruited and randomly assigned to the placebo group (n=20) to receive 3 times a day placebo capsules; and probiotics group (n=20), to receive 3 times a day probiotic supplement. The demographic data, anthropometric measurements, IBD Quality of Life Questionnaire and blood samples will be collected at baseline and after 6 weeks of follow up. Interleukin-6, interleukin-1,interleukin-10 IL-10, C-reactive protein, tumor necrosis factor-alpha and complete blood count (CBC) will be measured.
The results will approve or disapprove the beneficial effect of using probiotics as adjuvant therapy for UC patients to raise the immune system as well as improving their quality of life.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
To meet the objectives of the study, an interventional double-blind randomized clinical trial (RCT) design will be used in this study. A placebo group will be included in parallel with the treatment group in this trail. Forty patients (aged 35-65 years) who diagnosed with mild to moderately active UC will be recruited conveniently from the gastroenterology section, the IBD clinic at the Jordan University Hospital, Amman, Jordan. Patients who meet the inclusion criteria and agree to participate will be centrally randomized to probiotic supplementation group or placebo group using computer-generated random numbers, that balanced allocation to groups A and B: in successive blocks each containing 20 patients each stratified by gender. The duration of the intervention will be 6 weeks.
For the participants, the Jordan University Hospital setting will be utilized for data collection. The patients will be recruited over 12 months and all patients will be asked to sign a written informed consent before enrollment. The patients will randomly be assigned to the placebo group (n=20), to receive 3 times a day placebo capsules contain polysaccharides, without any viable probiotics matching the probiotic capsules in appearance, smell, and taste; and probiotics group (n=20), to receive 3 times a day probiotic supplement. The administration of supplements will be under the supervision of the treating physician. The blood sample will be collected at baseline and at the end of 6 weeks of follow up.
The demographic data of each subject will be collected such as; gender, age, body mass index (BMI), tumor location, malignant tumors stage, tumor differentiation, educational level, occupation, family history, smoking, dietary and physical activity. At baseline and end of the follow-up, IBD Quality of Life Questionnaire will be collected and blood sample tests will be withdrawn and the following biochemical variables will be measured: immunoglobulin G, immunoglobulin M, immunoglobulin A, interleukin-6 (IL-6), C-reactive protein (CRP), interleukin-1(IL-1), interleukin-10(IL-10), interleukin-12 (IL-12), Tumor necrosis factor-alpha (TNF-α) and complete blood count (CBC).
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Amman, Jordan
- Jordan University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female patients,
- Age between 35 -65 years,
- Diagnosed with UC established by colonoscopy and histology, and suffering from mild to moderate UC as defined by Modified Mayo Disease Activity Index (MMDAI) (score 3-9).
Exclusion Criteria:
- Patients with age <35 years, >65 years,
- Pregnancy, planned pregnancy, breastfeeding women,
- Evidence of severe disease (MMDAI >10),
- Concurrent enteric infection,
- Use of antibiotics,
- Change in the dose of oral 5-aminosalicylic acid (5-ASA) within the past 4weeks, and use of rectal 5-ASA or steroids within 7 days before entry into the study,
- Received any investigational medicines within 3months,
- If they have significant hepatic, renal, endocrine, respiratory, neurological, or cardiovascular diseases
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Probiotic Formula Capsule
In this intervention arm, the patients will receive oral viable capsules of probiotic contain (1*10 10 colony-forming unit (CFU)/g) of lactobacillus (Lactobacillus rhamnosus , Lactobacillus acidophilus, Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus gasseri, Lactobacillus plantarum) and bifidobacteria (Bifidobacterium lactis, Bifidobacterium breve, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis) species three times a per day
|
The Probiotic will be coded in a specific label by a researcher who will not be in contact with the participants and administrated randomly based on gender in a double-blind manner.
The patient will receive 2 bottles of the drug every 2 weeks and will be followed weekly for 6 weeks.
Other Names:
|
Placebo Comparator: Placebos
In this intervention arm Placebo arm received three oral viable capsules daily, containing polysaccharides, without any viable probiotics matching the probiotic capsules in appearance, smell, and taste.
|
The Placebos will be coded in a specific label by a researcher who will not be in contact with the participants and administrated randomly based on gender in a double-blind manner.
The patient will receive 2 bottles of the placebo every 2 weeks and will be followed weekly for 6 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The level of Immunoglobulin (Ig) A
Time Frame: Through study completion, an average of 1 year
|
The level of Immunoglobulin (Ig) A in mg/dL at both baseline and end line of follow up
|
Through study completion, an average of 1 year
|
The level of Immunoglobulin (Ig) G
Time Frame: Through study completion, an average of 1 year
|
The level of Immunoglobulin (Ig) G in mg/dL at both baseline and end line of follow up
|
Through study completion, an average of 1 year
|
The level of Immunoglobulin (Ig) M
Time Frame: Through study completion, an average of 1 year
|
The level of Immunoglobulin (Ig) M in mg/dL at both baseline and end line of follow up
|
Through study completion, an average of 1 year
|
The Level of Interleukin (IL)-6
Time Frame: Through study completion, an average of 1 year
|
The Level of Interleukin (IL)-6 in pg/ml at both baseline and end line of follow up
|
Through study completion, an average of 1 year
|
The Level of Interleukin (IL)-1
Time Frame: Through study completion, an average of 1 year
|
The Level of Interleukin (IL)-1 in pg/ml at both baseline and end line of follow up
|
Through study completion, an average of 1 year
|
The Level of Interleukin (IL)-10
Time Frame: Through study completion, an average of 1 year
|
The Level of Interleukin (IL)-10 in pg/ml at both baseline and end line of follow up
|
Through study completion, an average of 1 year
|
The Level of Tumor Necrosis Factor (TNF)-α
Time Frame: Through study completion, an average of 1 year
|
The Level of TNF-α in pg/ml at both baseline and end line of follow up
|
Through study completion, an average of 1 year
|
The Level of C-reactive protein (CRP)
Time Frame: Through study completion, an average of 1 year
|
The Level of CRP in mg/ml at both baseline and end line of follow up
|
Through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of Life of patients
Time Frame: Through study completion, an average of 1 year
|
The average score of the general quality of life (QoL) subscales assessed by the Short Quality of Life in Inflammatory Bowel Disease Questionnaire (SIBDQ).
The SIBDQ contains 10 questions for 4 functional scales (Bowel, Systemic, emotional, and social).
For each question, there a regraded responses on a7-point Likert scale ranging from one (representing the ''worst'' aspect) to seven (representing the ''best'' aspect).
Total SIBDQ scores range from 10 to 70, with higher scores reflecting better well-being.
|
Through study completion, an average of 1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The level of White blood cell count (WBC)
Time Frame: Through study completion, an average of 1 year
|
The level of WBC as cells*10^9/l at both baseline and end line of follow up
|
Through study completion, an average of 1 year
|
The level of red blood cell count (RBC)
Time Frame: Through study completion, an average of 1 year
|
The level of RBC as cells*10^12/l at both baseline and end line of follow up
|
Through study completion, an average of 1 year
|
The mean corpuscular volume (MCV)
Time Frame: Through study completion, an average of 1 year
|
The MCV in fl at both baseline and end line of follow up
|
Through study completion, an average of 1 year
|
The mean corpuscular hemoglobin (MCH)
Time Frame: Through study completion, an average of 1 year
|
The MCH in pg at both baseline and end line of follow up
|
Through study completion, an average of 1 year
|
The mean corpuscular hemoglobin concentration (MCHC)
Time Frame: Through study completion, an average of 1 year
|
The MCH in g/dl at both baseline and end line of follow up
|
Through study completion, an average of 1 year
|
The Platelet count
Time Frame: Through study completion, an average of 1 year
|
The Platelet count as cells 10^9/ll at both baseline and end line of follow up
|
Through study completion, an average of 1 year
|
The of Hemoglobin
Time Frame: Through study completion, an average of 1 year
|
The Hemoglobin in g/dl at both baseline and end line of follow up
|
Through study completion, an average of 1 year
|
The mean platelet volume (MPV)
Time Frame: Through study completion, an average of 1 year
|
The MPV in fl at both baseline and end line of follow up
|
Through study completion, an average of 1 year
|
The level of lymphocytes
Time Frame: Through study completion, an average of 1 year
|
The number of lymphocytes cells as cells*10^9/L at both baseline and end line of follow up
|
Through study completion, an average of 1 year
|
The level of Monocytes
Time Frame: Through study completion, an average of 1 year
|
The number of Monocytes cells at both baseline and end line of follow up
|
Through study completion, an average of 1 year
|
The level of eosinophils
Time Frame: Through study completion, an average of 1 year
|
The number of eosinophils cells at both baseline and end line of follow up
|
Through study completion, an average of 1 year
|
The level of basophils
Time Frame: Through study completion, an average of 1 year
|
The number of basophils cells at both baseline and end line of follow up
|
Through study completion, an average of 1 year
|
The level of neutrophils
Time Frame: Through study completion, an average of 1 year
|
The number of neutrophils cells at both baseline and end line of follow up
|
Through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Mohammed Isam Yamani, Pro.Dr, University of Jordan
- Study Chair: Reema F Tayyem, Pro.Dr, University of Jordan
Publications and helpful links
General Publications
- Abraham BP, Quigley EMM. Probiotics in Inflammatory Bowel Disease. Gastroenterol Clin North Am. 2017 Dec;46(4):769-782. doi: 10.1016/j.gtc.2017.08.003. Epub 2017 Oct 3.
- Araya M, Morelli L, Reid G, et al. (2002), Guidelines for the evaluation of probiotics in food. Joint FAO/WHO Working Group report on drafting guidelines for the evaluation of probiotics in food, London; (ON, Canada). ftp://ftp.fao.org/es/esn/food/wgreport2.pdf (Accessed 19March, 2018).
- Bamias G, Corridoni D, Pizarro TT, Cominelli F. New insights into the dichotomous role of innate cytokines in gut homeostasis and inflammation. Cytokine. 2012 Sep;59(3):451-9. doi: 10.1016/j.cyto.2012.06.014. Epub 2012 Jul 12.
- Bengtsson J, Adlerberth I, Ostblom A, Saksena P, Oresland T, Borjesson L. Effect of probiotics (Lactobacillus plantarum 299 plus Bifidobacterium Cure21) in patients with poor ileal pouch function: a randomised controlled trial. Scand J Gastroenterol. 2016 Sep;51(9):1087-92. doi: 10.3109/00365521.2016.1161067. Epub 2016 May 6.
- Cai S, Kandasamy M, Rahmat JN, Tham SM, Bay BH, Lee YK, Mahendran R. Lactobacillus rhamnosus GG Activation of Dendritic Cells and Neutrophils Depends on the Dose and Time of Exposure. J Immunol Res. 2016;2016:7402760. doi: 10.1155/2016/7402760. Epub 2016 Jul 20.
- Dargahi N, Johnson J, Donkor O, Vasiljevic T, Apostolopoulos V. Immunomodulatory effects of probiotics: Can they be used to treat allergies and autoimmune diseases? Maturitas. 2019 Jan;119:25-38. doi: 10.1016/j.maturitas.2018.11.002. Epub 2018 Nov 12.
- de Moreno de Leblanc A, Del Carmen S, Zurita-Turk M, Santos Rocha C, van de Guchte M, Azevedo V, Miyoshi A, Leblanc JG. Importance of IL-10 modulation by probiotic microorganisms in gastrointestinal inflammatory diseases. ISRN Gastroenterol. 2011;2011:892971. doi: 10.5402/2011/892971. Epub 2011 Feb 8.
- Feuerstein JD, Moss AC, Farraye FA. Ulcerative Colitis. Mayo Clin Proc. 2019 Jul;94(7):1357-1373. doi: 10.1016/j.mayocp.2019.01.018. Erratum In: Mayo Clin Proc. 2019 Oct;94(10):2149.
- Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, Ziade N, Hashash JG. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019 Dec;65(12):100851. doi: 10.1016/j.disamonth.2019.02.004. Epub 2019 Mar 2.
- Guandalini S, Sansotta N. Probiotics in the Treatment of Inflammatory Bowel Disease. Adv Exp Med Biol. 2019;1125:101-107. doi: 10.1007/5584_2018_319.
- Kabeerdoss J, Devi RS, Mary RR, Prabhavathi D, Vidya R, Mechenro J, Mahendri NV, Pugazhendhi S, Ramakrishna BS. Effect of yoghurt containing Bifidobacterium lactis Bb12(R) on faecal excretion of secretory immunoglobulin A and human beta-defensin 2 in healthy adult volunteers. Nutr J. 2011 Dec 23;10:138. doi: 10.1186/1475-2891-10-138.
- Kaplan GG, Ng SC. Globalisation of inflammatory bowel disease: perspectives from the evolution of inflammatory bowel disease in the UK and China. Lancet Gastroenterol Hepatol. 2016 Dec;1(4):307-316. doi: 10.1016/S2468-1253(16)30077-2. Epub 2016 Nov 10.
- Konishi H, Fujiya M, Tanaka H, Ueno N, Moriichi K, Sasajima J, Ikuta K, Akutsu H, Tanabe H, Kohgo Y. Probiotic-derived ferrichrome inhibits colon cancer progression via JNK-mediated apoptosis. Nat Commun. 2016 Aug 10;7:12365. doi: 10.1038/ncomms12365.
- Agraib LM, Yamani MI, Tayyem R, Abu-Sneineh AT, Rayyan YM. Probiotic supplementation induces remission and changes in the immunoglobulins and inflammatory response in active ulcerative colitis patients: A pilot, randomized, double-blind, placebo-controlled study. Clin Nutr ESPEN. 2022 Oct;51:83-91. doi: 10.1016/j.clnesp.2022.08.020. Epub 2022 Aug 20.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019/385
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ulcerative Colitis
-
Ferring PharmaceuticalsCompletedActive Ulcerative Colitis | Remission of Ulcerative ColitisCanada
-
Palatin Technologies, IncRecruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis Acute | UlcerativeUnited States
-
Theravance BiopharmaCompletedUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateUnited States, Georgia, Moldova, Republic of, Romania
-
Rise Therapeutics LLCUniversity of Colorado, Denver; Mayo ClinicRecruitingUlcerative Colitis | Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic | Ulcerative Colitis Chronic MildUnited States
-
Assistance Publique - Hôpitaux de ParisMRSU 938 - Research Center of Saint AntoineNot yet recruitingPediatric Ulcerative Colitis in RemissionFrance
-
Protagonist Therapeutics, Inc.CompletedUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic SevereUnited States, Austria, Bulgaria, Canada, Georgia, Germany, Hungary, Italy, Korea, Republic of, Poland, Russian Federation, Serbia, Ukraine
-
Theravance BiopharmaCompletedActive Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy SubjectsUnited States
-
Altheus Therapeutics, Inc.UnknownUlcerative Colitis | Left-sided Ulcerative Colitis | Distal Ulcerative ColitisUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...University Medical Center Groningen; UMC UtrechtRecruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis AcuteNetherlands
-
Immune PharmaceuticalsUnknownUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateIsrael
Clinical Trials on Probiotic Formula Capsule
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...CompletedIrritable Bowel Syndrome
-
University of Sao PauloUniversity of Sao Paulo General HospitalUnknownAsthma OccupationalBrazil
-
Istituto Clinico HumanitasRecruiting
-
China Medical University HospitalGlac Biotech Co., LtdCompletedProbiotics Infant Formula | Infants HealthTaiwan
-
Mead Johnson NutritionCompleted
-
Chung Shan Medical UniversityCompleted
-
King Hussein Cancer CenterWithdrawn
-
Fudan UniversityInner Mongolia Yili Industrial Group Co., LtdCompletedObesity | AdiposityChina
-
University of MalayaCompleted
-
Laval UniversityLallemand Health SolutionsCompleted